Literature DB >> 27270274

Relationship between Fosfomycin Exposure and Amplification of Escherichia coli Subpopulations with Reduced Susceptibility in a Hollow-Fiber Infection Model.

Brian VanScoy1, Jennifer McCauley1, Sujata M Bhavnani1, Evelyn J Ellis-Grosse2, Paul G Ambrose3.   

Abstract

Understanding the relationship between antibiotic exposure and amplification of bacterial subpopulations with reduced drug susceptibility over time is important for evaluating the adequacy of dosing regimens. We utilized a hollow-fiber infection model to identify the fosfomycin intravenous dosing regimens that prevented the amplification of Escherichia coli bacterial subpopulations with reduced fosfomycin susceptibility. The challenge isolate was E. coli ATCC 25922 (agar MIC with glucose-6-phosphate, 1 mg/liter; agar MIC without glucose-6-phosphate, 32 mg/liter). The fosfomycin dosing regimens studied were 1 to 12 g every 8 h for 10 days to approximate that planned for clinical use. The studies included a no-treatment control regimen. Two bacterial subpopulations were identified, one with reduced susceptibility with agar MIC values ranging from 32 to 128 mg/liter and the other resistant with agar MIC values of 256 to >1,024 mg/liter on plates containing 5× and 256× the baseline MIC value, respectively. An inverted-U-shaped function best described the relationship between the amplification of the two bacterial subpopulations and drug exposure. The lowest fosfomycin dosing regimen that did not amplify a bacterial subpopulation with reduced susceptibility was 4 g administered every 8 h. Nearly immediate amplification of bacterial subpopulations with reduced susceptibility was observed with fosfomycin dosing regimens consisting of 1 to 2 g every 8 h. These data will be useful to support the selection of fosfomycin dosing regimens that minimize the potential for on-therapy amplification of bacterial subpopulations with reduced susceptibility.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27270274      PMCID: PMC4997836          DOI: 10.1128/AAC.00355-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa.

Authors:  G L Drusano; Robert A Bonomo; Nadzeya Bahniuk; Juergen B Bulitta; Brian Vanscoy; Holland Defiglio; Steven Fikes; David Brown; Sarah M Drawz; Robert Kulawy; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

2.  The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance.

Authors:  Vincent H Tam; Arnold Louie; Mark R Deziel; Weiguo Liu; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  NIH-98-134: Contemporary Medicine as Presented by its Practitioners Themselves, Leipzig, 1923:217-250.

Authors:  Hugo Schulz; Ted Crump
Journal:  Nonlinearity Biol Toxicol Med       Date:  2003-07

4.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual
Journal:  Arch Intern Med       Date:  2008-09-22

5.  Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model.

Authors:  Brian D VanScoy; Rodrigo E Mendes; Mariana Castanheira; Jennifer McCauley; Sujata M Bhavnani; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2014-07-28       Impact factor: 5.191

6.  Evaluation of Daptomycin Exposure and Efficacy and Safety Endpoints To Support Risk-versus-Benefit Considerations.

Authors:  Sujata M Bhavnani; Paul G Ambrose; Jeffrey P Hammel; Christopher M Rubino; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

7.  Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections.

Authors:  Husnu Pullukcu; Meltem Tasbakan; Oguz Resat Sipahi; Tansu Yamazhan; Sohret Aydemir; Sercan Ulusoy
Journal:  Int J Antimicrob Agents       Date:  2007-01       Impact factor: 5.283

Review 8.  The epidemiology of urinary tract infection.

Authors:  Betsy Foxman
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

9.  Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.

Authors:  Annika I Nilsson; Otto G Berg; Olle Aspevall; Gunnar Kahlmeter; Dan I Andersson
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

10.  Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Alan Forrest; Ronald N Jones; Paul G Ambrose
Journal:  Clin Infect Dis       Date:  2003-07-17       Impact factor: 9.079

View more
  13 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

3.  Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.

Authors:  Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 4.  The Potential Role of Fosfomycin in Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.

Authors:  Grace Li; Joseph F Standing; Julia Bielicki; William Hope; John van den Anker; Paul T Heath; Mike Sharland
Journal:  Drugs       Date:  2017-06       Impact factor: 9.546

5.  Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome.

Authors:  Iain J Abbott; Elke van Gorp; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

6.  Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomycin for Injection) against KPC-Producing Klebsiella pneumoniae.

Authors:  John K Diep; Rajnikant Sharma; Evelyn J Ellis-Grosse; Cely S Abboud; Gauri G Rao
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 7.  Fosfomycin: Pharmacological, Clinical and Future Perspectives.

Authors:  Anneke Corinne Dijkmans; Natalia Veneranda Ortiz Zacarías; Jacobus Burggraaf; Johan Willem Mouton; Erik Bert Wilms; Cees van Nieuwkoop; Daniel Johannes Touw; Jasper Stevens; Ingrid Maria Catharina Kamerling
Journal:  Antibiotics (Basel)       Date:  2017-10-31

8.  Relationship between Gepotidacin Exposure and Prevention of On-Therapy Resistance Amplification in a Neisseria gonorrhoeae Hollow-Fiber In Vitro Infection Model.

Authors:  Brian D VanScoy; Nicole E Scangarella-Oman; Steven Fikes; Sharon Min; Jianzhong Huang; Karen Ingraham; Sujata M Bhavnani; Haley Conde; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

9.  Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial.

Authors:  Jesús Sojo-Dorado; Inmaculada López-Hernández; Clara Rosso-Fernandez; Isabel M Morales; Zaira R Palacios-Baena; Alicia Hernández-Torres; Esperanza Merino de Lucas; Laura Escolà-Vergé; Elena Bereciartua; Elisa García-Vázquez; Vicente Pintado; Lucía Boix-Palop; Clara Natera-Kindelán; Luisa Sorlí; Nuria Borrell; Livia Giner-Oncina; Concha Amador-Prous; Evelyn Shaw; Alfredo Jover-Saenz; Jose Molina; Rosa M Martínez-Alvarez; Carlos J Dueñas; Jorge Calvo-Montes; Jose T Silva; Miguel A Cárdenes; María Lecuona; Virginia Pomar; Lucía Valiente de Santis; Genoveva Yagüe-Guirao; María Angeles Lobo-Acosta; Vicente Merino-Bohórquez; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  JAMA Netw Open       Date:  2022-01-04

10.  Quantification of Fosfomycin in Combination with Nine Antibiotics in Human Plasma and Cation-Adjusted Mueller-Hinton II Broth via LCMS.

Authors:  Kelvin Kau-Kiat Goh; Wilson Ghim-Hon Toh; Daryl Kim-Hor Hee; Edwin Zhi-Wei Ting; Nathalie Grace Sy Chua; Farah Iffah Binte Zulkifli; Li-Jiao Sin; Thuan-Tong Tan; Andrea Lay-Hoon Kwa; Tze-Peng Lim
Journal:  Antibiotics (Basel)       Date:  2022-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.